Polling Questions

Participate in polls relating to the screening, accurate diagnosis, treatment and long-term management of HSDD and see how your answers relate to your colleague's responses.

In the RECONNECT study, efficacy results of bremelanotide as compared to placebo with respect to the female sexual function index desire domain became evident:
posted 06/21/2022
In two Phase 3 clinical studies in premenopausal women with hypoactive sexual desire disorder (HSDD), bremelanotide:
posted 06/03/2022
Excitatory and inhibitory pathway(s) regulating sexual response dysfunction(s) that may lead to HSDD is(are):
posted 05/19/2022
The RECONNECT study of ~1,200 women diagnosed with HSDD self-administering either bremelanotide or placebo evidenced that:
posted 04/28/2022
According to the webcast by Drs Parish and Kellogg Spadt, Hypoactive Sexual Desire Disorder (HSDD): Screening, Diagnosis, Management and Treatment Options, which HSDD treatment Dr Kellogg Spadt mentions is commonly referred to online as 'the sex injector?'
posted 04/07/2022
As discussed in the webcast HSDD: A Case presentation: Novel Treatments For Female Hypoactive Sexual Desire Disorder (HSDD) with Lisa Larkin, MD, Female Sexual Dysfunction (FSD)…
posted 03/10/2022
Which of the following is correct, according to Dr Pelin Batur's webcast 50 Shades of Low Sexual Desire in Women, regarding treatment of female hypoactive sexual desire disorder (HSDD)?
posted 03/03/2022
As discussed in the webcast From Bench to Bedside: Novel Treatments For Female Hypoactive Sexual Desire Disorder (HSDD) with Stanley E. Althof PhD, IF and Maureen Whelihan MD, FACOG, Bremelanotide is:
posted 02/18/2022
According to a survey of women, published by Dr Kingsberg, "When sex is good it adds 15-20% value to a relationship; but and when sex is bad/non-existent it disproportionately drains the relationship of all positive value by 50-70%."
posted 09/03/2021
As published in JAMA, in 1999, what was the most prevalent sexual complaint of the >1,700 women aged 18-59 interviewed by the National Health and Social Life Survey?
posted 05/28/2021
As discussed by Dr Krychman in his webcast Desire for Desire, which chronic and prevalent medical conditions are important to address when treating FSD/HSDD?
posted 04/01/2021
Which of the following is correct, according to Dr Pelin Batur's webcast 50 Shades of Low Sexual Desire in Women, regarding treatment of female hypoactive sexual desire disorder (HSDD)?
posted 03/04/2021
Which is true, according to Dr Pelin Batur's webcast 50 Shades of Low Sexual Desire in Women, regarding treatment of female hypoactive sexual desire disorder (HSDD)?
posted 02/18/2021
According to Dr Harsh, which of the following is true of bremelanotide?
posted 02/05/2021
Which of the following is correct per Ekta Kapoor, MBBS of Mayo Clinic?
posted 01/22/2021
According to an article by JN Sobecki et al, what percentage of Ob/Gyns routinely ask patients about their sexual satisfaction?
posted 01/07/2021
According to a 2009 study*, the percentage of women suffering from HSDD who turn to the internet or magazines to alleviate their condition, risking using unregulated or suspiciously marketed products, is:
posted 12/18/2020
As explained by Dr Simon in his program, Treatments for Low Sexual Desire with Associated Distress in Pre and Postmenopausal Women, what is the daily ratio of testosterone/estrogen production in adult women (excluding during pregnancy)?
posted 12/10/2020
As presented by Drs Larkin and Pickle, of the women who reported distressing sexual problems in the PRESIDE study, how many sought formal medical care?'
posted 12/04/2020
As presented by Drs Parish and Kellogg Spadt, which HSDD treatment Dr Kellogg Spadt mentions is commonly referred to online as 'the sex injector?'
posted 11/19/2020
As presented by Drs Simon and Dominguez-Bali, which of the following does Dr Dominguez-Bali recommend with regard to a sexual disorder that does not produce stress or discomfort?
posted 11/12/2020
As presented by Drs Kingsberg and Zuponcic, of the 31,581 women, 18+ years old surveyed in the PRESIDE study:
posted 11/05/2020
As presented by Dr Clayton, some recommended interventions for the clinical management of HSDD are:
posted 10/16/2020
Which of the following behavioral intervention(s) in addition to pharmacotherapy is/are generally recommended for Hypoactive Sexual Desire Disorder management?
posted 09/30/2020
Which of the following clinical perspectives is true?
posted 09/02/2020
Safety of Flibanserin in Women Treated with SSRI/SNRI Antidepressants: Results of a Randomized, Placebo-Controlled Study
posted 06/20/2019
Investigational Treatment Options for HSDD: New Avenues
posted 05/31/2019
Diagnosing and Managing HSDD from a Primary Care Perspective
posted 04/23/2019
Her Experience with HSDD: A Clinical Case Explored
posted 03/15/2019
Bremelanotide: A Novel Treatment for Female HSDD
posted 03/01/2019
Excitatory and inhibitory pathway(s) regulating sexual response dysfunction(s) that may lead to HSDD is(are):
posted 02/21/2019
According to Dr Larkin, one of the reasons primary care clinicians have difficulty diagnosing FSD is:
posted 01/31/2019
The sexual tipping point (STP) model is?
posted 11/29/2018
Evidence-based psychological therapy(ies) tested as effective for improving sexual desire in women is/are:
posted 11/07/2018
To improve sexual desire and treat hypoactive sexual desire disorder (HSDD) in cancer patients, Dr Lynn recommends:
posted 11/02/2018
In a post-hoc analysis and published article by SG Kornstein et al on Change in Body Weight with Flibanserin, what was the percentage of (unexpected) weight loss in both pre- and postmenopausal women after 24 weeks?
posted 10/04/2018
The diagnostic and statistical manual (DSM) was revised in 2013 as DSM-5 from the previous DSM-IV version to incorporate which change:
posted 08/23/2018
In their briefing document, Division Summary, phase 3 placebo-controlled trials, on flibanserin, depression, and SS/RIs, the FDA states:
posted 08/02/2018
Studies regarding activation/redistribution patterns of brain blood flow as it applies to female sexual response, show that:
posted 07/19/2018
The melanocortin agonist bremelanotide has shown to modulate dopamine release by which of the following mechanisms:
posted 06/15/2018
All successful HSDD therapies improve desire and lower distress by:
posted 06/07/2018
Which of the following changes in the New FDA draft guidance are considered positive by the majority of the sexual medical experts community:
posted 05/03/2018
The melanocortin agonist bremelanotide is believed to increase sexual desire in women by which of the following mechanisms:
posted 03/26/2018
In order to meet the diagnostic criteria for HSDD, which of the following other disorders/dysfunctions must be excluded?
posted 02/01/2018
What effect do neurotransmitters such as dopamine/norepinephrine have on sexual desire?
posted 10/12/2017
Which of the following are recommended to initiate a discussion about sexual health?
posted 09/29/2017
What is the benefit of using the Decreased Sexual Desire Screener (DSDS)?
posted 09/07/2017
Issues that confound trial design and/or interpretation of SSE trial results for many clinical trials include:
posted 08/18/2017
A method(s) used for evaluating/diagnosing HSDD, as well as measuring the clinical success of treatment is/are:
posted 08/04/2017
Which of the following statements is true?
posted 07/13/2017
Why should we assess sexual function in our female patients?
posted 06/30/2017
The most effective treatment for female sexual disorders involves
posted 06/16/2017
Female sexual function is modulated by
posted 04/14/2017
A current model of the important factors affecting the female sexual response includes
posted 03/24/2017
What would you find most problematic in using Sexually Satisfying Events (SSEs) to evaluate sexual desire or arousal disorders in women?
posted 02/07/2017
In which situation do you believe the best outcome from HSDD occurs?
posted 01/17/2017
Which of the following issues do you believe most negatively affect female sexual dysfunction?
posted 12/16/2016
Which tip do you believe makes health care professionals most comfortable when discussing sexuality with their patients?
posted 12/01/2016
When assessing a patient for female sexual dysfunction, which of the following factors do you believe is the most important to evaluate?
posted 11/18/2016
Which issue do you believe most complicates the diagnosis and treatment of HSDD?
posted 10/25/2016
Dr. Parish would like to know...
What percentage of your patients express concern about the negative effect of FSD/HSDD on their relationship with their sexual partners?
posted 04/28/2016
Drs. Althof and Whelihan would like to know...
What percentage of your patients seeking treatment for FSD/HSDD have been referred by other clinicians/clinics?
posted 03/07/2016
Dr. Krychman would like to know...
What percentage of your female patients links sex to overall general health, wellness, and quality of life?
posted 01/25/2016
Dr. Clayton would like to know...
What percentage of your patients do you currently screen for HSDD using the DSDS?
posted 12/20/2015
Dr. Simon would like to know…
In the past 3 months, what percentage of your patients have asked about treatment for HSDD?
posted 12/09/2015
Dr. Kingsberg would like to know...
How comfortable do you feel screening for and diagnosing HSDD?
posted 10/14/2015
What percentage of your female patients do you screen for hypoactive sexual desire disorder?
posted 11/15/2013

Warning: Undefined array key 67 in /home/vpscogni/public_html/hd/herDesire/polling.php on line 1676